NANO Nanobiotix SA

NANOBIOTIX ANNONCE LA PREMIERE INJECTION DE NBTXR3 A UN PATIENT ATTEINT D’UN CANCER DU PANCREAS AINSI QUE LES NOTIFICATIONS “SAFE TO PROCEED” DE LA FDA AMERICAINE POUR DEUX AUTRES ESSAIS CLINIQUES

NANOBIOTIX ANNONCE LA PREMIERE INJECTION DE NBTXR3 A UN PATIENT ATTEINT D’UN CANCER DU PANCREAS AINSI QUE LES NOTIFICATIONS “SAFE TO PROCEED” DE LA FDA AMERICAINE POUR DEUX AUTRES ESSAIS CLINIQUES
FR
13/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Emira Sagaama ... (+3)
  • Emira Sagaama
  • Hela Zarrouk
  • Oliver Metzger
Emira Sagaama ... (+3)
  • Emira Sagaama
  • Hela Zarrouk
  • Oliver Metzger
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
 PRESS RELEASE

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1...

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1 Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch